[199 Pages Report] The Inhaled Nitric Oxide Market size was estimated at USD 778.21 million in 2023 and expected to reach USD 821.09 million in 2024, at a CAGR 5.83% to reach USD 1,157.38 million by 2030.
Inhaled nitric oxide (iNO) is a pulmonary vasodilator used in intensive care medicine to manage acute and chronic pulmonary disorders. It is administered through inhalation, directly reaching the lungs and improving oxygenation by dilating pulmonary blood vessels without significantly affecting blood pressure in other body parts. Its primary use is in neonatal and pediatric populations for conditions including persistent pulmonary hypertension of the newborn (PPHN) and acute respiratory distress syndrome (ARDS). The rising incidence of neonatal conditions requiring iNO therapy, such as PPHN, and an increase in cases of ARDS have significantly propelled the need for inhaled nitric oxide. Additionally, technological advancements enabling portable NO delivery systems have expanded the applicability of the treatments in different care settings, including home care. The ongoing research and potential new indications for iNO in adults with pulmonary diseases offer growth avenues for the market. However, the high cost and stringent regulatory requirements for approval associated with inhaled nitric oxide pose significant barriers to the entry of new players and can limit market growth. Moreover, the exploration of new therapeutic indications and innovations in administration technology that are expected to reduce costs and improve accessibility are promising areas for the inhaled nitric oxide market.
Application: Increasing incidences of chronic obstructive pulmonary disease
Inhaled nitric oxide (iNO) is significant in managing acute respiratory distress syndrome by improving oxygenation and reducing pulmonary arterial pressures. Its vasodilatory effects in ventilated lung regions optimize the matching of ventilation and perfusion, enhancing arterial oxygenation. Chronic obstructive pulmonary disease patients may experience acute exacerbations characterized by worsening of their respiratory symptoms. iNO has been explored as a potential therapy during these exacerbations to improve gas exchange and decrease pulmonary hypertension, which is often associated with COPD. Recent studies have investigated inhaled nitric oxide as an adjunctive treatment for severe malaria. The anti-inflammatory properties of iNO and its ability to improve blood flow and reduce endothelial dysfunction indicate that it is expected to alleviate the vascular complications associated with severe malaria infections. iNO is a well-established therapy for newborns with hypoxic respiratory failure, particularly those with persistent pulmonary hypertension of the newborn (PPHN). iNO improves oxygenation and minimizes the need for extracorporeal membrane oxygenation (ECMO) in affected neonates by selectively dilating the pulmonary vessels. The role of inhaled nitric oxide in tuberculosis (TB) treatment is an emerging area of research, focusing on its potential antibacterial effects, especially against drug-resistant TB strains. iNO’s ability to directly kill or inhibit the growth of Mycobacterium tuberculosis in vitro suggests that it is expected to serve as an adjunctive therapy to enhance the efficacy of existing TB treatment regimens.
End-Users: Growing deployment of inhaled nitric oxide devices in hospitals for neonatal and intensive care units
Clinics play an essential role in adopting and applying inhaled nitric oxide therapies. These facilities cater to outpatient services and may not always possess the extensive medical infrastructure found in larger hospitals. Clinics are increasingly incorporating this therapy into their respiratory care offerings with advancements in portable nitric oxide delivery systems. The adoption of inhaled nitric oxide in clinics is pivotal in providing accessible care, particularly in rural or underserved areas, facilitating early intervention and potentially reducing hospital admissions. Hospitals represent the most significant end-users of inhaled nitric oxide, largely owing to their capacity to treat severe and acute conditions requiring intensive care and monitoring. Inhaled nitric oxide is primarily used in neonatal units for babies with persistent pulmonary hypertension of the newborn and in intensive care units for adults suffering from severe acute respiratory distress syndrome (ARDS). Hospitals’ adoption and use of inhaled nitric oxide are supported by comprehensive infrastructure, including specialized delivery systems, monitoring equipment, and trained respiratory therapists, to ensure effective and safe administration of the treatment.
Regional Insights
In the Americas, particularly in the United States and Canada, the adoption of inhaled nitric oxide is increasing rapidly owing to the high prevalence of respiratory diseases and the strong presence of healthcare facilities with advanced technological setups. The FDA’s proactive role in approving inhaled nitric oxide products for various medical conditions, including pulmonary arterial hypertension and hypoxic respiratory failure, has bolstered the growth of the inhaled nitric oxide market. Moreover, major players in the pharmaceutical and medical device industries in this region are intensively involved in R&D activities, aiming to expand the application range of inhaled nitric oxide therapy. The EMEA region exhibits a dynamic market for inhaled nitric oxide, with Europe majorly contributing to adoption and innovation. The increasing incidence of neonatal conditions and respiratory diseases in this region has heightened the need for effective therapeutic solutions, including inhaled nitric oxide. Regulatory bodies in Europe, such as the European Medicines Agency (EMA), have laid down stringent guidelines and approval processes, ensuring the safety and efficacy of inhaled nitric oxide products. In the Middle East and Africa, the market is gradually expanding, primarily driven by healthcare infrastructure developments and growing awareness about advanced treatment modalities. The APAC region is witnessing the rapid adoption of inhaled nitric oxide therapies owing to rising healthcare expenditure, an increasing population base, and a growing number of preterm birth incidences. Countries such as China, Japan, and India are at the forefront of this adoption, driven by ongoing healthcare reforms, increasing investments in healthcare infrastructure, and rising awareness about innovative therapeutic options, including inhaled nitric oxide. Furthermore, the presence of a significant number of generic pharmaceutical manufacturers in this region offers cost-effective solutions, making inhaled nitric oxide therapy more accessible to a larger patient population.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Inhaled Nitric Oxide Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Inhaled Nitric Oxide Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Inhaled Nitric Oxide Market, highlighting leading vendors and their innovative profiles. These include Air Liquide SA, Beyond Air, Inc., GE HealthCare Technologies, Inc., Getinge AB, Linde PLC, Mallinckrodt PLC, Matheson Tri-Gas, Inc. by Mitsubishi Chemical Group Corporation, Merck KGaA, NIOX Group PLC, Perma Pure LLC by Halma PLC, SOL Group, Third Pole, Inc., and VERO Biotech Inc..
Market Segmentation & Coverage
This research report categorizes the Inhaled Nitric Oxide Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Application
- Acute Respiratory Distress Syndrome
- Chronic Obstructive Pulmonary Disease
- Malaria Treatment
- Neonatal Respiratory Treatment
- Tuberculosis Treatment
- End-Users
- Clinic
- Hospital
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
- What is the market size and forecast of the Inhaled Nitric Oxide Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Inhaled Nitric Oxide Market?
- What are the technology trends and regulatory frameworks in the Inhaled Nitric Oxide Market?
- What is the market share of the leading vendors in the Inhaled Nitric Oxide Market?
- Which modes and strategic moves are suitable for entering the Inhaled Nitric Oxide Market?
US $
Euro €
GBP £